Newswise — For the first time, scientists have shown that a protein in the nucleus of victims' cells triggers progression of smallpox-related illnesses, a finding that could help prevent use of such viruses as bioterrorism weapons.
Purdue University scientists found that poxviruses move to the second and third stages of development by recruiting a protein, called TATA-binding protein, in the nucleus of mammals' cells.
"This protein is required for activation of the middle- and late-stage poxvirus genes," said Steven Broyles, a Purdue biochemistry professor. "In the past, we were just groping around. We now have a model for how the poxvirus growth process is orchestrated."
Their research results are published in the current issue of the Journal of Virology, a publication of the American Society for Microbiology. The study is currently available online.
Although the last naturally occurring case of smallpox was in Somalia in 1977, experts believe that the disease and related viruses could be used as biological weapons.
Though most potential biological weapons occur naturally, it's possible that bioterrorists could engineer viruses and bacteria to increase their virulence, make them resistant to currently used vaccines and drugs, or partner two biological agents to make a new, more lethal illness, according to the Centers for Disease Control and Prevention (CDC).
People no longer are vaccinated against or exposed to smallpox since it was eradicated. However, laboratory stockpiles of the virus still exist in the United States and other places around the world, CDC experts report. If some of the virus were released, either in its common or a mutated form, a health crisis could result.
Two types of the most common smallpox form, variola major, almost always are fatal, according to CDC statistics. Overall, the average death rate of all types of variola major is about 30 percent.
In order to guard against a terrorist-planted or spontaneous outbreak, major scientific efforts are under way to learn how smallpox and similar illnesses so effectively can halt normal cell activity in mammals, including humans. If scientists understand the biochemical changes that allow pox viruses to cause illness, and also the processes that allow the disease-causing organisms to mutate, it may be possible to create new vaccines and treatments that could be used should outbreaks occur.
Smallpox, monkey pox, cowpox and camel pox, all members of the virus genus Orthopox, are large brick-shaped molecules. Because the pox viruses have the largest genomes of all animal viruses, the finding that these diseases recruit a victim's proteins was surprising, Broyles said.
"Poxviruses are very adept at clamping down on the cell and not letting go," he said. "These viruses are proficient in shutting down everything the host cell does."
Some poxviruses are more dangerous for animals than for people, but all cause everything from blisters to death. Monkey pox, a rare member of this virus group that usually infects monkeys, rodents and children in central Africa, appeared in the upper Midwest United States in 2003. Monkey pox, though not as virulent as smallpox, produces many of the same symptoms, including fever, pus-filled blisters and respiratory problems.
The U.S. monkey pox cases were the first known human incidents in the Western Hemisphere. An imported rodent apparently spread the disease to some pet shop prairie dogs. The people who contracted the disease had direct contact with the animals.
In all, the CDC identified 72 cases. No one died in the U.S. outbreak, although in Africa the fatality rate is as high as 10 percent.
Another of the poxviruses, vaccinia, has a genome that is 97 percent identical to the smallpox genome. Because of this similarity, vaccinia has been used as a vaccine against smallpox.
Broyles and his research team used vaccinia to find out how poxviruses progress. They knew that specific vaccinia genes are expressed at specific stages of the disease, but scientists didn't know what activated these genes, causing a cascade of events culminating in the virus controlling the host cell.
The Purdue researchers studied vaccinia's genetic makeup at the intermediate and late stages of the biochemical process that leads to a takeover of victims' cells. The scientists analyzed the resulting data and discovered that the pox virus was grabbing the TATA-binding protein (TBP) from the host cell.
TBP acts as a timer switch to turn on poxvirus intermediate- and late-stage genes, Broyles said.
"We identified TATA-binding protein as being at the center of the ability to activate the promoters - the genes that make the virus' progression and control possible," he said. "The virus begins the process by grabbing the protein out of the host nucleus. The protein comes out and hits the trigger on the virus to start the chain of events that allows the virus to attack the cell."
Now the researchers are investigating what signals the virus' genes to grab the TBP and what signals TBP to hit the trigger.
The other researchers involved in this Purdue-funded study were Bruce Knutson, a Purdue biochemistry doctoral student; Xu Liu, now a researcher at U.S. Patent and Trade Office in Alexandria, Va.; and Jaewook Oh, now with the Department of Microbiology at the University of Pennsylvania School of Medicine.
Related Web sites:
Steven Broyles: http://www.biochem.purdue.edu/faculty/broyles.html
Purdue Department of Biochemistry: http://www.biochem.purdue.edu/
Centers for Disease Control and Prevention: http://www.cdc.gov
Journal of Virology: http://jvi.asm.org/
A publication-quality photo is available at http://news.uns.purdue.edu/images/+2006/broyles-poxvirus.jpg
Abstract on the research in this release is available at:
http://news.uns.purdue.edu/UNS/html4ever/2006/060717.Broyles.poxvirus.html
RSS